Can-Fite BioPharma (NYSE:CANF) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report issued on Sunday. The firm set a “hold” rating on the stock.

Can-Fite BioPharma Price Performance

Shares of CANF opened at $2.10 on Friday. Can-Fite BioPharma has a one year low of $1.66 and a one year high of $3.33. The company has a market cap of $7.43 million, a P/E ratio of -1.17 and a beta of 1.53. The firm has a 50 day simple moving average of $2.16 and a two-hundred day simple moving average of $2.14.

Can-Fite BioPharma (NYSE:CANF) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). Can-Fite BioPharma had a negative net margin of 1,027.46% and a negative return on equity of 113.75%. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.20 million. On average, analysts expect that Can-Fite BioPharma will post -0.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Schechter Investment Advisors LLC bought a new stake in shares of Can-Fite BioPharma in the fourth quarter worth $44,000. Virtu Financial LLC bought a new stake in shares of Can-Fite BioPharma in the second quarter worth $52,000. Finally, Armistice Capital LLC bought a new stake in shares of Can-Fite BioPharma in the fourth quarter worth $340,000. 21.00% of the stock is currently owned by institutional investors and hedge funds.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.